Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras-Reference-Cited by-同舟云学术

Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras

Published:2009-09 Issue:7262 Volume:461 Page:411-414
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Lauchle Jennifer O.,Kim Doris,Le Doan T.,Akagi Keiko,Crone Michael,Krisman Kimberly,Warner Kegan,Bonifas Jeannette M.,Li Qing,Coakley Kristen M.,Diaz-Flores Ernesto,Gorman Matthew,Przybranowski Sally,Tran Mary,Kogan Scott C.,Roose Jeroen P.,Copeland Neal G.,Jenkins Nancy A.,Parada Luis,Wolff Linda,Sebolt-Leopold Judith,Shannon Kevin

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature08279.pdf

Reference25 articles.

1. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nature Rev. Cancer 3, 11–22 (2003)

2. Schubbert, S., Shannon, K. & Bollag, G. Hyperactive Ras in developmental disorders and cancer. Nature Rev. Cancer 7, 295–308 (2007)

3. Van Etten, R. A. & Shannon, K. M. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 6, 547–552 (2004)

4. Lauchle, J. O., Braun, B. S., Loh, M. L. & Shannon, K. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatr. Blood Cancer 46, 579–585 (2006)

5. Shannon, K. M. et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N. Engl. J. Med. 330, 597–601 (1994)

Cited by 126 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology Group;Cancer Discovery;2024-06-11

2. Emerging In Vitro and In Vivo Models: Hope for the Better Understanding of Cancer Progression and Treatment;Advanced Biology;2024-04-05

3. Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management;Journal of Clinical Medicine;2024-03-20

4. Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations;Cancer Discovery;2024-03-08

5. Chromosomal and Genomic Alterations in Pediatric AML;Pediatric Oncology;2024